Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
Sponsor: Exela Pharma Sciences, LLC.
Terminated
Low recruitment rate
This PHASE3 trial investigates Spinal Fusion and is currently terminated or withdrawn. Exela Pharma Sciences, LLC. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE3
Status: Enrolling By Invitation → Terminated
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2019 — Aug 2019 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Aug 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Exela Pharma Sciences, LLC.
For direct contact, visit the study record on ClinicalTrials.gov .